Online ISSN 2313-1519
Print    ISSN 1812-2892
Abstract - Evaluation of Body Composition in Patients with Psoriasis
[PDF]           
Hülya Nazik, Mehmet Kamil Mülayim, Derya Korkut Saridağ, Perihan Öztürk

ABSTRACT

Objective: Psoriasis is a chronic inflammatory skin disease with a complex etiopathogenesis including genetic predisposition, immune dysfunction and environmental factors. Chronic inflammation leads to the development of vascular and metabolic disorders. The bioimpedance method is an easy and useful method for evaluating of body composition. In this study, it was aimed to investigate body composition, demographic, clinical and laboratory data in patients with psoriasis and to compare them with healthy controls.

Material and Methods: Sociodemographic characteristics of the participants, duration of disease, concomitant systemic diseases, family history of psoriasis, presence of psoriatic arthritis and current treatments were questioned. Body composition of the participants was determined by Tanita Body Composition Analyzer type BC-418 (Tokyo, Japan), and in blood samples glucose, total cholesterol, HDL, LDL, triglyceride and insulin levels were determined by autoanalysers.

Results: HOMA-IR, triglyceride, BMI, metabolic age and fat percentage were significantly higher in the psoriasis group, whereas the control group had higher body density, lean mass, mineral percentage and total body fluid. In this study, it was found that as the insulin resistance, BMI and fat ratio increased, the severity of the disease increased in patients with psoriasis.  Also BMI increased in patients with longer disease duration. Topical and conventional therapies had no significant effect on laboratory and body composition parameters.

Conclusion: In the light of the data obtained in this study, it was concluded that some metabolic markers and body composition parameters were negatively affected in patients with psoriasis and were associated with disease severity.

Key words: psoriasis, disease severity, BMI, body composition, fat percentage, insulin resistance

Corresponding Author: Hülya Nazik, MD, Assistant Professor, Department of Dermatology,  Kahramanmaraş Sütçü İmam University, Kahramanmaraş, 46100, Turkey. Tel.:+90 (505) 501 9161, fax:+90 (344) 300 3434. E-mail: dr.hulyagul@hotmail.com

References

  1. Alper S, Atakan N, Gürer MA, Onsun N, Özarmağan G. Updated Turkish Guidelines for the Management of Psoriasis with Biologic Agents. Turkderm. 2010; 44:105-12. https://doi.org/10.4274/turkderm.44.105
  2. Daudén E, Castañeda S, Suárez C, García-Campayo J, Blasco AJ, Aguilar MD, et al. Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. J Eur Acad Dermatol Venereol. 2013; 27:1387-404. https://doi.org/10.1111/jdv.12024
  3. Çetin I, Muhtaroğlu S, Yılmaz B, Kurtoğlu S. Evaluation of segmental body composition by gender in obese children using bioelectric impedance analysis method. Dicle Medical Journal. 2015; 42(4):449-454. https://doi.org/10.5798/diclemedj.0921.2015.04.0607
  4. Kim N, Thrash B, Menter A. Comorbidities in psoriasis patients. Semin Cutan Med Surg.  2010; 29:10-5. https://doi.org/10.1016/j.sder.2010.01.002
  5. Atakan N, Doğan S. Psoriasis sistemik bir hastalık mıdır? Turk J Dermatol. 2012; 6:119-22.
  6. Kimball AB, Guérin A, Tsaneva M, Yu AP, Wu EQ, Gupta SR, et al. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol. 2011; 25:157-63. https://doi.org/10.1111/j.1468-3083.2010.03730.x
  7. Onsun N, Su Ö, Eriş Z, Davutoğlu M, Cebeci F, Şenocak M. Psoriasisli hastalarda diyabet görülme sıklığına karşılık diyabetli hastalarda psoriasis görülme sıklığı. Turkderm. 2010; 44:12-4.
  8. Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005; 141:1527-34. https://doi.org/10.1001/archderm.141.12.1527
  9. Wolk K, Mallbris L, Larsson P, Rosenblad A, Vingård E, Stahle M. Excessive Body Weight and Smoking Associates with a High Risk of Onset of Plaque Psoriasis. Acta Derm Venereol. 2009; 89:492-7. https://doi.org/10.2340/00015555-0711
  10. Sakai R, Matsui S, Fukushima M, Yasuda H, Miyauchi H, Miyachi Y. Prognostic factor analysis for plaque psoriasis. Dermatology. 2005; 211:103-6. https://doi.org/10.1159/000086437
  11. Naldi L, Addis A, Chimenti S, Giannetti A, Picardo M, Tomino C, et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the psocare Project. Dermatology. 2008; 217:365-73. https://doi.org/10.1159/000156599
  12. Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011; 25:1007-11. https://doi.org/10.1111/j.1468-3083.2011.04065.x
  13. Tamer F, Gürer MA. The effect of psoriasis treatment on body composition, components of metabolic syndrome and psoriatic arthritis. Turkderm. 2015; 49:41-4. https://doi.org/10.4274/turkderm.80090
  14. Friis NU, Hoffmann N, Gyldenlove M, Skov L, Vilsboll T, Knop FK, et al. Glucose metabolism in patients with psoriasis. Br J Dermatol. 2018; PMID: 30376181. https://doi.org/10.1111/bjd.17349
  15. Polic MV, Miskulin M, Smolic M, Kralik K, Miskulin I, Berkovic MC, et al. Psoriasis Severity-A Risk Factor of Insulin Resistance Independent of Metabolic Syndrome. Int J Environ Res Public Health. 2018; 13:15(7). https://doi.org/10.3390/ijerph15071486
  16. Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012; 97:2969–89. https://doi.org/10.1210/jc.2011-3213
  17. Kaya H, Özçelik O. Vücut bileşimlerinin değerlendirilmesinde vücut kitle indeksi ve biyoelektrik impedans analiz metodlarının etkinliğinin yaş ve cinsiyete göre karşılaştırılması. FÜ Sağ Bil Tıp Derg. 2009; 23:1-5.
  18. Mele C, Tagliaferri MA, Saraceno G, Mai S, Vietti R, Zavattaro M, et al. Serum uric acid potentially links metabolic health to measures of fuel use in lean and obese individuals. Nutr Metab Cardiovasc Dis. 2018; 28(10):1029-1035. https://doi.org/10.1016/j.numecd.2018.06.010
  19. Soysal P, Ates Bulut E, Yavuz I, Isik AT. Decreased Basal Metabolic Rate Can Be an Objective Marker for Sarcopenia and Frailty in Older Males. J Am Med Dir Assoc. 2018; 16. pii: S1525-8610(18)30362-1. https://doi.org/10.1016/j.jamda.2018.07.001
Volume 1, Number 51 (2019)